NEW PODCAST!

The NASH Tsunami In Diabetes

Getting Ahead of the Rising Tide in Fatty Liver Disease

Recent prospective studies suggest that more than half of patients with Type 2 diabetes have concomitant NAFLD and more than one in three have NASH.

Other recent research tells us that patients with both diseases are at significantly increased risk of heart disease and cancer and are likely to have lower quality-of-life scores when compared to patients with T2D alone.

Join endocrinologist Kenneth Cusi, MD, forecaster/podcaster Roger Green, and their renowned guests to focus on the scale of the problem (HINT: large and scary!) and practical things you can do today to diagnose and treat these patients more effectively.

new podcast!! ⤵

S3-E1.2 - NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

S3-E40.5 – From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.

SurfingNASH.Com is honored to have the following sponsors

Would you like to participate ask a question join the surfers in our next episode?

S3-E40.3 – Importance of Early Diagnosis in Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.

S3-E40.2 – A Simple Diagnostic Algorithm for Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the elegant one-page diagnostic algorithm they recommend for diagnosing Lean NASH in “normal” BMI patients with signs of liver disease.

S3-E40 – Best Practices in Lean NASH: Authors Provide Back Story

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent Clinical Practice Update in Gastroenterology titled “Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.”

S3-E39.5 – From The Vault: Early, Accurate Patient Information Matters

In this conversation from September 2021, Anthony Villiotti of NASH kNOWledge joins Louise Campbell and Roger Green to discuss his “biggest story of the summer:” two publications, on demonstrating that NASH prevalence and incidence may be far higher than we believe and another demonstrating how limited public knowledge about NASH is today.

S3-E39.4 – Patient Follow-Up Challenges in Modeling NASH Diagnostics

Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

Experience Nudge Learning!
Interested in a new way of learning?